Trials / Suspended
SuspendedNCT04828174
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
The Safety and Clinical Efficacy of Human TRBC1 CAR-T Cell Therapy for Patients With Relapsed/Refractory TRBC1 Positive T Cell Hematological Maliganacies
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive T-cell hematological maliganacies
Conditions
- Peripheral T Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Anaplastic Lymphoma
- Acute T Cell Leukemia
- T-lymphoblastic Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anti-TRBC1 CAR-T cell therapy | TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1 |
Timeline
- Start date
- 2021-03-31
- Primary completion
- 2023-11-26
- Completion
- 2023-11-26
- First posted
- 2021-04-01
- Last updated
- 2023-11-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04828174. Inclusion in this directory is not an endorsement.